The 60-Second Answer:
Yes, elinzanetant may be a safe, non-hormonal option for hot flashes after breast cancer when prescribed and monitored by an oncology team. The OASIS-4 clinical trial found meaningful relief during endocrine therapy, but U.S. approval is currently for vasomotor symptoms due to menopause, not specifically breast cancer treatment.
Elinzanetant After Breast Cancer
Hot flashes and night sweats can disrupt sleep and breast cancer recovery. These menopausal symptoms are especially difficult for women who cannot use hormone therapy.
Elinzanetant, sold as Lynkuet, is a new drug that does not contain estrogen or progesterone. The FDA approved it in October 2025 for moderate-to-severe vasomotor symptoms due to menopause. However, the current U.S. label does not specifically cover symptoms associated with endocrine therapy for breast cancer. The European Union authorization does include this use.[1,2]
For a Wise Woman entering her Second Spring, that distinction matters because availability differs by country.
Menopause Changes Heat Control
Estrogen helps stabilize KNDy neurons in the brain’s temperature-control center. Menopause, ovarian suppression, or drugs that block the effects of estrogen can make them overactive. The comfortable temperature range narrows, triggering flushing, chills, and night sweats.
Elinzanetant works by blocking NK1 and NK3 receptors, including signaling from a protein called neurokinin B. Neurokinin plays a role in triggering hot flashes, while NK1 may affect sleep. This does not stop the ovaries from producing hormones and is not hormonal therapy.[3]
OASIS-4 Supports Elinzanetant
The phase 3 OASIS 4 trial studied 474 women aged 18 to 70 with hormone receptor-positive breast cancer, or high risk. Participants received tamoxifen or an aromatase inhibitor, sometimes with the ovarian function suppressor goserelin or leuprorelin.[4]
Eligible women were experiencing 35 or more moderate-to-severe VMS per week caused by hormone therapy. Researchers assessed moderate-to-severe VMS frequency and severity, sleep, and patients’ quality of life. They also examined whether patients had received tamoxifen or another endocrine regimen.
Participants were assigned to receive elinzanetant for 52 weeks or placebo for 12 weeks followed by elinzanetant for 40 weeks. At week 12, the average change in daily moderate-to-severe VMS frequency was minus 7.8 episodes with elinzanetant and minus 4.2 in groups receiving the placebo. A reduction of at least 50% occurred in 74.3% versus 35.8%, meaning considerably fewer in the placebo group reached that threshold.[4]
Results from the OASIS 4 clinical trial showed that elinzanetant reduces the frequency and severity of symptoms. Fewer VMS after week 1 and fewer after week 12 occurred with treatment. More participants taking elinzanetant were experiencing mild-to-moderate VMS with an average severity below baseline.
Elinzanetant was effective and well tolerated by women experiencing moderate to severe symptoms across hormone treatment groups. However, the industry-funded clinical trial did not test recurrence, survival, or better cancer outcomes, and it cannot establish safety beyond one year.
| Treatment | How It Works | Breast Cancer Evidence | Main Cautions |
|---|---|---|---|
| Elinzanetant | Blocks NK1 and NK3 receptors | Phase 3 OASIS-4 | Drowsiness, liver monitoring, interactions |
| Fezolinetant, Veozah | Blocks NK3 receptors | Limited cancer-specific evidence | Liver injury and interactions |
| Venlafaxine | Alters serotonin and norepinephrine | Established supportive-care evidence | Nausea, blood pressure, withdrawal |
| Gabapentin | Changes nerve signaling | May relieve hot flashes in women | Dizziness and sedation |
| Acupuncture | May influence nerve regulation | Mixed evidence | Variable response |
Night Sweats And Sleep May Improve
OASIS-4 participants reported better sleep and fewer hot flashes and night sweats without added hormones. Fatigue and somnolence can still cause daytime impairment.
Breast Cancer Safety Needs Context
Common side effects include headache, fatigue, dizziness, and sleepiness. The U.S. label warns about liver-enzyme elevations, daytime impairment, pregnancy loss, seizure risk, and CYP3A4 interactions. Liver tests are required before treatment and after three months; grapefruit and strong CYP3A4 inhibitors or inducers should be avoided.[1]
OASIS-4 included women with a history of breast cancer, but evidence remains limited for male patients, pregnancy, advanced breast cancer, and metastatic breast cancer. Individual oncology review is essential.
FDA Approval Has A Narrow Scope
Search wording such as “FDA approves elinzanetant for breast cancer hot flashes” can mislead. The FDA approves Lynkuet for moderate-to-severe VMS due to menopause, while the EU authorization also covers vasomotor symptoms associated with adjuvant endocrine breast cancer treatment.[1,2]
A Safe Start Requires Oncology Review
- Track hot flashes for seven days, including severity, timing, night sweats, and sleep disruption.
- Ask your oncologist whether Lynkuet suits your cancer history, liver and kidney health, seizure history, pregnancy potential, and current endocrine medicines.
- Complete baseline ALT, AST, alkaline phosphatase, and bilirubin tests. Repeat liver testing at three months or sooner if symptoms suggest injury.
- If prescribed, the labeled U.S. dose is 120 mg, two 60 mg capsules, once at bedtime, with or without food. Do not adjust it yourself.
- Review prescriptions, supplements, and grapefruit use for interactions.
- Reassess relief and side effects at weeks 1, 4, and 12. Avoid driving when sleepy or dizzy.
- Never stop endocrine therapy without your cancer team. Severe symptoms can lead to women stopping their breast cancer treatment prematurely, which may compromise care.
Frequently Asked Questions
Is Elinzanetant Safe With Tamoxifen?
OASIS-4 included tamoxifen and aromatase-inhibitor users, with or without ovarian suppression. Elinzanetant was effective and well tolerated across these groups. Long-term cancer safety and personal drug interactions still require oncology review.
Does Elinzanetant Differ From Veozah?
Yes. Elinzanetant blocks NK1 and NK3 receptors, while fezolinetant, sold as Veozah, targets NK3. Elinzanetant has direct phase 3 evidence in women receiving hormone treatment for breast cancer.
What Side Effects Can Elinzanetant Cause?
Common effects are headache, fatigue, dizziness, and sleepiness. Liver-enzyme elevations and important medication interactions are possible. Report dark urine, yellowing skin, persistent nausea, or unusual fatigue promptly.
Can Elinzanetant Improve Sleep Without Hormones?
Yes, OASIS-4 participants reported better sleep without hormonal therapies. Relief may reflect fewer nighttime vasomotor symptoms and dual neurokinin action. Individual results vary, and daytime sleepiness remains possible.
How Quickly Can Hot Flashes Improve?
Benefits appeared during the first week and were formally assessed at weeks 4 and 12. By week 12, 74.3% of treated participants achieved at least a 50% reduction. Not everyone responds, so track symptoms with your clinician.
Expert Angle: Treatment Adherence
The important research question extends beyond whether elinzanetant reduces the frequency of hot flashes. Vasomotor symptoms have a negative impact on patients’ quality of life and can lead to them stopping breast cancer treatment prematurely. Future trials should test whether sustained symptom control improves endocrine adherence and ultimately supports better cancer outcomes.
Continue Your Journey
Your Second Spring can include relief without compromising informed cancer care. Explore How Can Breast Cancer Survivors Safely Treat Hot Flashes Without Using Hormones? to compare medicines, acupuncture, cooling tools, and practical questions for your next oncology appointment.
References
- U.S. Food and Drug Administration. Lynkuet (elinzanetant) Prescribing Information. Revised October 2025. NDA 219469. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf
- European Medicines Agency. Lynkuet: EPAR Medicine Overview. Authorized November 17, 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/lynkuet
- Pinkerton JV, Simon J, Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(14):1165-1175. doi:10.1001/jama.2024.14618.
- Cardoso F, Parke S, Brennan DJ, et al. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2415566.
- ClinicalTrials.gov. OASIS-4. NCT05587296. https://clinicaltrials.gov/study/NCT05587296
